Figure 4.

Ad5/3-CMV-mCD40L enhances DC therapy but not adoptive T-cell therapy. (A) B16.OVA and (B) B16.F10 tumors were injected subcutaneously in immunocompetent C57BL/6 mice. Viruses was injected intratumorally three times at 2×10⁸ VP. (A) CD8-enriched OT-1 T cells (1.5 × 10⁶ cells) were injected intraperitoneally once and (B) dendritic cells (DCs, 1×10⁶ cells) were injected intratumorally three times between virus injections (arrows). Tumor growth was monitored every other day. Virus and DCs in combination significantly reduced tumor growth as compared with other groups. Data presented as mean ± SEM. Tumor growth is expressed as percentage increase from first day of virus injection. ***p < 0.001.